Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olorofim vs AmBisome in Invasive Aspergillosis
NCT05101187Phase 3Completed
- Sponsor
- F2G
- Start
- Apr 2022
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 21
01
Overview
A Phase 3 trial of olorofim in invasive aspergillosis (IA), sponsored by F2G. Started Apr 2022; status: completed.
02
Drugs
olorofim
03
Conditions
invasive aspergillosis (IA)
Beyond the preview
Go deeper on NCT05101187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05101187.